Cargando…
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression. Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones. HDACs are dysregulated in many cancers, making them a the...
Autores principales: | Suraweera, Amila, O’Byrne, Kenneth J., Richard, Derek J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884928/ https://www.ncbi.nlm.nih.gov/pubmed/29651407 http://dx.doi.org/10.3389/fonc.2018.00092 |
Ejemplares similares
-
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013) -
HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015) -
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013) -
Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs)
por: Mackmull, Marie-Therese, et al.
Publicado: (2015) -
In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
por: Friedrich, Annabelle, et al.
Publicado: (2020)